NexGel NXGL 深 沪
等待开盘 05-19 09:30:00 美东时间
0.511
+0.001
+0.20%
华盛通- 最 高0.5744
- 今 开0.50
- 成交量 12.14万股
- 最 低 0.50
- 昨 收 0.51
- 总市值 466.60万
- 52周最高 2.8899
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 0.4811
- 委 比 82.08%
- 总股本 913.11万
- 历史最高 5.10
- 量 比 0.96
- 振 幅 14.59%
- 历史最低 0.4811
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NexGel Q1 2026 Earnings Call Transcript
NexGel (NASDAQ:NXGL) held its first-quarter earnings conference call on Friday....
05-16 00:25
NexGel Q1 EPS $(0.11) Misses $(0.07) Estimate, Sales $2.650M Miss $3.909M Estimate
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 22.22 percent decrease over losses of $(0.09) per share from the same
05-15 05:30
Nexgel to report first-quarter results, host conference call
Nexgel to report first-quarter results, host conference call Nexgel to release first-quarter 2026 results May 15, 2026. Conference call set for May 15 at 12:00 p.m. ET, with webcast available via Events and Presentations . Disclaimer: This news brief was created by Public Technologies (PUBT) using g
05-12 22:27
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
NEXGEL, Inc. announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to its Board of Directors. Sequence LifeScience, led by Kieser and Harris, recently secured a $5.5 million strategic investment to acquire Celularity Inc.'s degenerative disease segment. Adam Levy, CEO of NEXGEL, highlighted the transformative impact of this partnership and welcomed the new board members, emphasizing their industry experience and strategic cont...
05-06 13:00
NEXGEL Appoints Ian Blackman as Chief Financial Officer
NEXGEL, Inc. has appointed Ian Blackman, CPA, as Chief Financial Officer to oversee the acquisition of Celularity's regenerative biomaterial products and drive growth. Blackman brings over 30 years of experience in scaling businesses and navigating complex transactions. His expertise will help integrate Celularity's assets, strengthen financial infrastructure, and enhance shareholder value. NEXGEL specializes in hydrogel products for healthcare a...
04-27 13:00
NexGel Q4 EPS $(0.12) Misses $(0.09) Estimate, Sales $2.796M Miss $3.240M Estimate
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same
04-01 05:34
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Nexgel updates its financial calendar; management hosts a conference call at 4:30 P.M. ET
Nexgel updates its financial calendar; management hosts a conference call at 4:30 P.M. ET NEXGEL will report financial results for the fourth quarter and full year ended December 31, 2025 after the market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET on March 31, 20
03-25 21:04
